# A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

> **NCT07065058** · PHASE1 · COMPLETED · sponsor: **Vincentage Pharma Co., Ltd** · enrollment: 24 (actual)

## Conditions studied

- Obesity &Amp; Overweight

## Interventions

- **DRUG:** Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

## Key facts

- **NCT ID:** NCT07065058
- **Lead sponsor:** Vincentage Pharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-01
- **Primary completion:** 2025-07-11
- **Final completion:** 2025-08-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07065058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07065058, "A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07065058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*